ATE168560T1 - Topische mittel zur transdermalen verabreichung von prodrugderivaten des morphins - Google Patents

Topische mittel zur transdermalen verabreichung von prodrugderivaten des morphins

Info

Publication number
ATE168560T1
ATE168560T1 AT91920399T AT91920399T ATE168560T1 AT E168560 T1 ATE168560 T1 AT E168560T1 AT 91920399 T AT91920399 T AT 91920399T AT 91920399 T AT91920399 T AT 91920399T AT E168560 T1 ATE168560 T1 AT E168560T1
Authority
AT
Austria
Prior art keywords
morphine
pct
transdermal administration
prodrug derivatives
topical agents
Prior art date
Application number
AT91920399T
Other languages
English (en)
Inventor
Hans Bundgaard
Lona Christrup
Joern Drustrup
Ann Fullerton
Martin Nicklasson
Original Assignee
Pharmacia & Upjohn Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Ab filed Critical Pharmacia & Upjohn Ab
Application granted granted Critical
Publication of ATE168560T1 publication Critical patent/ATE168560T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AT91920399T 1990-11-16 1991-11-11 Topische mittel zur transdermalen verabreichung von prodrugderivaten des morphins ATE168560T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9003665A SE9003665D0 (sv) 1990-11-16 1990-11-16 Morphine prodrugs

Publications (1)

Publication Number Publication Date
ATE168560T1 true ATE168560T1 (de) 1998-08-15

Family

ID=20380936

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91920399T ATE168560T1 (de) 1990-11-16 1991-11-11 Topische mittel zur transdermalen verabreichung von prodrugderivaten des morphins

Country Status (18)

Country Link
US (1) US5908846A (de)
EP (1) EP0557385B1 (de)
JP (1) JP3493434B2 (de)
AT (1) ATE168560T1 (de)
AU (1) AU655612B2 (de)
CA (1) CA2095223C (de)
DE (1) DE69129861T2 (de)
DK (1) DK0557385T3 (de)
ES (1) ES2121793T3 (de)
FI (1) FI932212A7 (de)
IE (1) IE913682A1 (de)
IL (1) IL99905A (de)
NO (1) NO931766D0 (de)
NZ (1) NZ240349A (de)
PT (1) PT99513B (de)
SE (1) SE9003665D0 (de)
WO (1) WO1992008459A1 (de)
ZA (1) ZA918512B (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5607691A (en) * 1992-06-12 1997-03-04 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
DE4403709A1 (de) * 1994-02-07 1995-08-10 Lohmann Therapie Syst Lts Pharmazeutische Zusammensetzung zur systemischen transdermalen Verabreichung mit dem Wirkstoff Morphin-6-glucuronid
JPH07267862A (ja) * 1994-03-29 1995-10-17 Sekisui Chem Co Ltd 経皮吸収貼付剤
DE19508664C2 (de) * 1995-03-14 2001-08-23 Christian Mignat Verwendung von Morphin-3-estern, Morphin-3-ester als solche und Verfahren zu deren Herstellung
WO1996028451A1 (en) * 1995-03-14 1996-09-19 Euroceltique S.A. Morphine-3-esters
GB9519363D0 (en) 1995-09-22 1995-11-22 Euro Celtique Sa Pharmaceutical formulation
DE19602963A1 (de) * 1995-12-20 1997-07-31 Nycomed Arzneimittel Gmbh Neue Morphinderivate, Verfahren zu deren Herstellung und deren Verwendung
DE19923551A1 (de) * 1999-05-21 2000-11-30 Lohmann Therapie Syst Lts Pharmazeutisches Präparat mit dem Wirkstoff Diamorphin und seine Verwendung in einem Verfahren zur Behandlung der Opiatsucht
ATE526950T1 (de) 1999-10-29 2011-10-15 Euro Celtique Sa Hydrocodon-formulierungen mit gesteuerter freisetzung
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
US20020013331A1 (en) * 2000-06-26 2002-01-31 Williams Robert O. Methods and compositions for treating pain of the mucous membrane
EP2283829A1 (de) 2000-10-30 2011-02-16 Euro-Celtique S.A. Hydrocodon-Formulierungen mit gesteuerter Freisetzung
US6569449B1 (en) * 2000-11-13 2003-05-27 University Of Kentucky Research Foundation Transdermal delivery of opioid antagonist prodrugs
KR100612398B1 (ko) * 2000-11-14 2006-08-16 바이탈 헬스 사이언시즈 피티와이 리미티드 포스페이트 유도체의 착체
AUPR549901A0 (en) * 2001-06-06 2001-07-12 Vital Health Sciences Pty Ltd Topical formulation containing tocopheryl phosphates
US20110104214A1 (en) 2004-04-15 2011-05-05 Purdue Pharma L.P. Once-a-day oxycodone formulations
IL158882A0 (en) * 2001-06-05 2004-05-12 Control Delivery Sys Inc Sustained-release analgesic compounds
AU2002317053B2 (en) * 2001-07-27 2004-08-05 Vital Health Sciences Pty Ltd Dermal therapy using phosphate derivatives of electron transfer agents
BR0215102A (pt) * 2001-12-13 2004-11-03 Vital Health Sciences Pty Ltd Transporte transdermal de compostos, formulação tópica, método para melhorar a absorção da pele, método para a terapia de reposição hormonal, uso de um ou mais derivados de fosfato de um composto hidróxi farmacêutico em um sistema de aplicação transdermal, sistema de aplicação transdermal, método para aplicação de um composto hidróxi farmacêutico a um indivìduo e para melhorar a eficácia de uma formulação
AU2002950713A0 (en) * 2002-08-09 2002-09-12 Vital Health Sciences Pty Ltd Carrier
AU2003285934A1 (en) * 2002-10-25 2004-05-25 Euro-Celtique S.A. Analogs and prodrugs of buprenorphine
US20040152769A1 (en) * 2002-11-09 2004-08-05 Ekwuribe Nnochiri Nkem Modified carbamate-containing prodrugs and methods of synthesizing same
BRPI0406484A (pt) * 2003-01-17 2005-12-06 Vital Health Sciences Pty Ltd Método de inibição da ocorrência de uma ou mais das seguintes condições: a proliferação de monócitos/macrófagos; ou a proliferação de células do músculo liso; ou a expressão de receptores de cd36; ou a absorção de lipoproteìna de baixa densidade - ldl oxidada, método de alìvio de sintomas de tratamento ou prevenção de aterosclerose; de diabetes; do mal de alzheimer, método de inibição da ocorrência da formação de placas no sistema vascular, método de alìvio da inflamação associada a ocorrência de uma ou de mais das seguintes condições: a proliferação de monócitos, a proliferação de células do músculo liso, a expressão de ldl oxidadas ou de receptor descontaminante, composição farmacêutica, uso de uma quantidade eficaz de um ou mais derivados ou fosfato de um ou mais agentes de transferência de elétrons conjuntamente com um veìculo ou um diluente apropriado, uso de uma quantidade eficaz de um ou mais derivados de fosfato de (alfa)-tocoferol conjuntamente com um veìculo ou um diluente apropriado e uso de uma quantidade eficaz de um ou mais derivados de fosfato de um ou mais agentes de transferência de elétrons selecionados do grupo que consiste em fosfato mono-tocoferila, fosfato de di-tocoferila e as misturas destes conjuntamente com um veìculo ou um diluente apropriado
AU2003901815A0 (en) * 2003-04-15 2003-05-01 Vital Health Sciences Pty Ltd Phosphate derivatives
CA2529983C (en) * 2003-07-25 2010-07-20 Euro-Celtique S.A. Preoperative treatment of post operative pain
PT1864987E (pt) 2004-02-06 2010-03-09 Euro Celtique Sa Processos para a produção de morfinonas protegidas em 3-o e carboxilatos de dienol e morfinonas protegidos em 3-o
LT2351555T (lt) 2004-02-23 2016-12-27 Euro-Celtique S.A. Piktnaudžiavimui atspari priemonė, skirta transderminiam opoido įvedimui
CA2557354C (en) 2004-03-03 2013-05-07 Vital Health Sciences Pty Ltd. Alkaloid formulations
MX2007015949A (es) * 2005-06-17 2008-03-07 Vital Health Sciences Pty Ltd Un vehiculo que comprende uno o mas derivados de fosfato de di- y/o mono-(agentes de transferencia de electrones) o complejos de los mismos.
WO2007070981A1 (en) * 2005-12-23 2007-06-28 Vital Health Sciences Pty Ltd Compounds having cytokine modulating properties
US9326979B2 (en) 2007-03-02 2016-05-03 Teika Pharmaceutical Co., Ltd. Medicinal composition for transdermal absorption, medicinal composition storing unit and transdermal absorption preparation using the same
US9511016B2 (en) * 2007-06-12 2016-12-06 Epicentrx, Inc. Topical composition for treating pain
US8354116B2 (en) * 2007-06-18 2013-01-15 Biochemics, Inc. Bifunctional synthetic molecules
US20090130048A1 (en) * 2007-11-19 2009-05-21 Oronsky Bryan Todd Topical Composition for Treating Pain
US8784872B2 (en) 2007-11-19 2014-07-22 Comgenrx, Inc. Formulation for decreasing tobacco, alcohol, drug or food consumption
WO2009158667A2 (en) * 2008-06-27 2009-12-30 Comgenrx, Inc. Povidone compositions for wound healing
CA2765836C (en) 2009-07-02 2014-10-07 Kempharm, Inc. Phenylethanoic acid, phenylpropanoic acid and phenylpropenoic acid conjugates and prodrugs of hydrocodone, methods of making and use thereof
UA102916C2 (uk) 2009-07-02 2013-08-27 Кемфарм, Інк. Композиція на основі кон'югату гідрокодону з бензойною кислотою, похідними бензойної кислоти або гетероарилкарбоновою кислотою, проліки, спосіб лікування від зловживань
US10849981B2 (en) 2009-07-02 2020-12-01 KemPham, Inc. Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof
US10071030B2 (en) 2010-02-05 2018-09-11 Phosphagenics Limited Carrier comprising non-neutralised tocopheryl phosphate
JP5806287B2 (ja) 2010-03-30 2015-11-10 フォスファジェニクス リミティド 経皮送達パッチ
KR20150036825A (ko) 2010-04-13 2015-04-07 나지브 바불 1-메틸-2''-6''-피페콜옥실리디드의 피부 약제학적 조성물 및 사용 방법
TWI590821B (zh) 2011-01-18 2017-07-11 輝瑞有限公司 固體分子分散液
WO2012122586A1 (en) 2011-03-15 2012-09-20 Phosphagenics Limited New composition
SG11201704178UA (en) 2014-11-25 2017-06-29 Kempharm Inc Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of oxycodone
MX383940B (es) 2015-12-09 2025-03-14 Phosphagenics Ltd Formulación farmacéutica que contiene tocol fosfato.
JP7198754B2 (ja) 2016-12-21 2023-01-04 アベーチョ バイオテクノロジー リミテッド 方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4626539A (en) * 1984-08-10 1986-12-02 E. I. Dupont De Nemours And Company Trandermal delivery of opioids
US4673679A (en) * 1986-05-14 1987-06-16 E. I. Du Pont De Nemours And Company Use of prodrugs of 3-hydroxymorphinans to prevent bitter taste upon buccal, nasal or sublingual administration
US4908389A (en) * 1986-08-27 1990-03-13 Warner-Lambert Company Penetration enhancement system
US4940586A (en) * 1987-02-26 1990-07-10 Alza Corporation Skin permeation enhancer compositions using sucrose esters
US4879297A (en) * 1987-06-01 1989-11-07 Warner-Lambert Company Fatty acids and their small chain esters as penetration enhancers in aqueous systems
US4891377A (en) * 1988-12-02 1990-01-02 Board Of Regents Acting For And On Behalf Of University Of Michigan Transdermal delivery of the narcotic analgesics etorphine and analogs
DE69122464T2 (de) * 1990-03-30 1997-02-20 Yasunori Morimoto Transdermal absorbierbares mittel mit morphin hydrochlorid
US5069909A (en) * 1990-06-20 1991-12-03 Cygnus Therapeutic Systems Transdermal administration of buprenorphine

Also Published As

Publication number Publication date
DK0557385T3 (da) 1999-04-26
FI932212L (fi) 1993-05-14
IL99905A0 (en) 1992-08-18
JPH06502422A (ja) 1994-03-17
IE913682A1 (en) 1992-05-20
WO1992008459A1 (en) 1992-05-29
NZ240349A (en) 1993-07-27
DE69129861D1 (de) 1998-08-27
EP0557385B1 (de) 1998-07-22
IL99905A (en) 1995-06-29
CA2095223A1 (en) 1992-05-17
AU655612B2 (en) 1995-01-05
ES2121793T3 (es) 1998-12-16
NO931766L (no) 1993-05-14
SE9003665D0 (sv) 1990-11-16
NO931766D0 (no) 1993-05-14
DE69129861T2 (de) 1999-04-01
JP3493434B2 (ja) 2004-02-03
FI932212A0 (fi) 1993-05-14
AU8938191A (en) 1992-06-11
PT99513A (pt) 1992-09-30
US5908846A (en) 1999-06-01
FI932212A7 (fi) 1993-05-14
CA2095223C (en) 2002-12-17
EP0557385A1 (de) 1993-09-01
PT99513B (pt) 1999-04-30
ZA918512B (en) 1992-08-26

Similar Documents

Publication Publication Date Title
DE69129861D1 (de) Topische mittel zur transdermalen verabreichung von prodrugderivaten des morphins
CY2431B1 (en) Novel phenanthridines substituted in the 6 position.
ATE185548T1 (de) Verwendung von n-arylmethylen ethylendiamintriacetate, n-arylmethylen iminodiacetat oder n,n'-diarylmethylen ethylendiamindiacetat gegen oxidativen stress
CY2473B1 (en) New phenanthridines.
MY119403A (en) Novel compounds with analgesic effect.
MD960330A (ro) Compuşi nepeptidilici, compoziţie farmaceutică pe baza acestora, metodă de tratament
NO308794B1 (no) Farmakologisk aktive pyridin-derivater, preparater inneholdende forbindelsene samt forbindelsenes anvendelse
PT1093819E (pt) Compostos e composicoes para fornecimento de agentes activos
ATE201597T1 (de) Verabreichung von riluzol zur behandlung von neuro-aids
NO942375L (no) Terapeutiske midler
IL133824A0 (en) Tetrazole derivatives, medicaments containing same and use thereof
WO1992019617A3 (en) Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
BR0009524A (pt) Uso de um composto, e, composição farmacêutica ou veterinaria
DE69731882D1 (de) Transdermal verabreichtes dextromethorphan als hustenmittel
GEP20032953B (en) Antitumor Agents
TR199900951T2 (xx) G���s kanserinin engellenmesi i�in y�ntemler.
IT1243193B (it) Composizioni farmaceutiche orali a base di melatonina
TR199801184T2 (xx) Analjezik tesirli yeni bile�ikler.
DK0669826T3 (da) (-)-Metrifonatholdigt lægemiddel
ES2097816T5 (es) Producto y su uso para el tratamiento de estados catabolicos que comprende ifg-1 autentico y cantidades hipocaloricas de nutrientes.
EP0348664A3 (de) Monoacetoacetine enthaltende pharmazeutische Zusammensetzungen zur Behandlung von Tumoren
ATE173925T1 (de) Lösliche calciumlaktat/chinoloncarbonsäuren komplexe als nichtreizende parenterale verabreichungsformen
ATA57894A (de) Mittel zur behandlung von osteoporose
NZ331374A (en) Phenanthridine compounds and pharmaceutical compositions thereof
DE69428276D1 (de) Insulinähnlicher wachstumfaktor ii als antitumormittel

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee